The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome
| Autor: | Alberto Forni, Alessandro Di Vilio, Alfonso Desiderio, Marino Scherillo, Giovanni Cimmino, Paolo Golino, Antonello D'Andrea, Fabio Pastore, Massimo Ragni, Vincenzo Russo, Juri Radmilovic, Gaetano Quaranta |
|---|---|
| Přispěvatelé: | Radmilovic, Juri, Di Vilio, Alessandro, D'Andrea, Antonello, Pastore, Fabio, Forni, Alberto, Desiderio, Alfonso, Ragni, Massimo, Quaranta, Gaetano, Cimmino, Giovanni, Russo, Vincenzo, Scherillo, Marino, Golino, Paolo |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Acute coronary syndrome
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Population lcsh:Medicine thrombocytopenia Review 030204 cardiovascular system & hematology Revascularization double antiplatelet therapy (DAPT) 03 medical and health sciences acute coronary syndrome (ACS) 0302 clinical medicine Internal medicine medicine cancer atrial fibrillation education education.field_of_study Chemotherapy business.industry lcsh:R Anticoagulant anticoagulant Cancer General Medicine medicine.disease Radiation therapy 030220 oncology & carcinogenesis Concomitant business |
| Zdroj: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 9, Iss 3926, p 3926 (2020) |
| Popis: | Among acute coronary syndrome (ACS) patients, 15% have concomitant cancer, especially in the first 6 months after their diagnosis, as well as in advanced metastatic stages. Lung, gastric, and pancreatic cancers are the most frequent malignancies associated with ACS. Chemotherapy and radiotherapy exert prothrombotic, vasospastic, and proinflammatory actions. The management of cancer patients with ACS is quite challenging: percutaneous revascularization is often underused, and antiplatelet and anticoagulant pharmacological therapy should be individually tailored to the thrombotic risk and to the bleeding complications. Sometimes oncological patients also show different degrees of thrombocytopenia, which further complicates the pharmacological strategies. The aim of this review is to summarize the current evidence regarding the treatment of ACS in cancer patients and to suggest the optimal management and therapy to reduce the risk of adverse coronary events after ACS in this high-risk population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|